**Transitional Nurse Practitioner**

**Scope of Practice**

|  |  |
| --- | --- |
| **Name of NP/TNP** |  |
| **Specialty** |  |
| **Local Health District** |  |

**A Nurse Practitioner (NP) is a registered nurse educated and authorised to function autonomously and collaboratively in an advanced and extended clinical role. The NP role includes the assessment and management of patients using nursing knowledge and skills and may include but is not limited to initiation of diagnostic investigations, prescribing of medications and direct referral of patients to other health care professionals. The NP role is grounded in the nursing profession’s values, knowledge, theories and practice and provides innovative and flexible health care delivery that complements other health care providers (ANMC 2006). NPs practice collaboratively as an interdependent member of the multidisciplinary health care team and provide autonomous, patient centred care.**

**The scope of practice (ScOP) of the NP is determined by the context of practice, the education and level of competence of the individual, policy and service requirements and forms part of the Nursing and Midwifery Board of Australia Safety & Quality Framework.**

**Each NP must develop an individual ScOP that reflects their expertise and competence. While the ScOP may be similar for NPs working in certain clinical specialties, it must reflect the capabilities, expertise and competence of the individual. Establishing and ensuring competence to practice within a ScOP is the responsibility of both the NP and employer. The employer and NP are to ensure the defined ScOP is evidence based and in accordance with the LHD policy requirements and the NMBA S&QF.**

**Clinical judgment regarding a particular clinical procedure or treatment plan is made by the NP in light of the clinical data presented by the patient and the diagnostic and treatment options available. In making clinical decisions the NP remains conscious of their level of expertise and utilise available resources and expertise of the multidisciplinary health care team.**

**The authorising legislation for the use, possession, supply and prescription of medications by NPs in NSW is the *Poisons and Therapeutic Goods Act 1966* and the *Poisons and Therapeutic Goods Regulation 2008.***

**Regulation of NPs is in accordance with the *Health Practitioner Regulation National Law (NSW) No 86a.***

**Practice will be in accordance with current best evidence and both relevant NSW Health and local LHD policies, procedures and guidelines.**

**Practice context/setting**

***Demographics and supporting services***

|  |
| --- |
|       |

**Model of care**

***Aim***

|  |
| --- |
| ***List the identified service gaps or needs the NP role/service aims to address – these will form the basis of evaluation***      |

**Service description**

***Target Population for Service***

|  |
| --- |
|       |

***Health Service Setting***

|  |
| --- |
|       |

***Facilities/Facility Where Nurse Practitioner Role or Service Operates***

|  |
| --- |
|  |

***Operational aspects***

|  |
| --- |
| ***Health***  |

**Parameters of practice**

***Elements of care***

|  |
| --- |
|       |

***Common presenting conditions and disease states managed by the NP (not exhaustive)***

|  |
| --- |
|       |

***Exclusions from care***

|  |
| --- |
|       |

***Process of care***

|  |
| --- |
| ***Referral pathway / initiation of contact with service***     ***Criteria for referral***     ***Prescribing and dispensing arrangements***     ***Diagnostic investigation arrangements******Other*** |

***Appended Formulary***

YES [ ]  Attached at Appendix A for approval

NO [ ]

**Exclusions:** A nurse practitioner must not prescribe, give a written or oral instruction or supply or administer medicines (1) that have not been approved by the Therapeutic Goods Administration outside the terms of the manufacturer’s product information (off-label) unless sufficient evidence to demonstrate safety.

***Specific procedural activities***

|  |
| --- |
|  |

***Collaborative arrangements (as required to facilitate access to MBS & PBS)***

|  |
| --- |
|       |

**Clinical Governance Arrangements**

***Part A: Study, clinical supervision and mentorship arrangements***

|  |
| --- |
|       |

***Part B: Describe who the NP role / service articulates into organisational governance arrangements***

|  |
| --- |
|       |

**Clinical resources**

|  |
| --- |
|       |

**Professional role activities**

***Clinical leadership, education and research***

|  |
| --- |
|       |

**Evaluation**

***Strategy for evaluation of model and ScOP review***

|  |
| --- |
|       |

***Performance Review***

|  |
| --- |
|       |

***The Multidisciplinary Support Committee agree that this scope of practice and model has been developed collaboratively and is supported practice for the named nurse practitioner.***

|  |  |  |
| --- | --- | --- |
| ***Multidisciplinary Support Committee Chair*** | ***Signature*** | ***Date agreed*** |
| ***Name:*** ***Position:***  |  |  |

**Nursing Executive acknowledgement**

|  |  |  |
| --- | --- | --- |
| ***Local Health District Director of Nursing and Midwifery Services*** | ***Signature*** | ***Date*** |
| ***Name:***  |  |  |
| ***Facility Director of Nursing and Midwifery Services Signature Date*** |
| ***Name:***  |  |  |

**Local Health District Chief Executive acknowledgement**

|  |  |  |
| --- | --- | --- |
| ***Name:***  | ***Signature*** | ***Date*** |
|  |  |

**Appendix A**

**Appended Drug Formulary**

**If an appended formulary is required, the template is to be completed and the formulary approved by the LHD CE.**

**Prescribing Reference:** *Nurse Practitioner / Transitional Nurse Practitioner to insert preferred prescribing resources / references*

***Dosages are not transcribed into formulary in order to avoid transcription error***

|  |  |  |  |
| --- | --- | --- | --- |
| **Class** | **Drug name****(generic)** | **Clinical presentation** | **Notes** |
|  |       |       | *Eg. CTO, SCM as appropriate* |
|  |       |       |       |

**Approval of Appended Nurse Practitioner Formulary**

**POISIONS AND THERAPEUTICS GOODS ACT 1966**

***Section 17A***

**Nurse Practitioner Authority to Possess, Use, Prescribe**

**or Supply Substances**

I,(***insert name of officer***) Chief Executive of (***insert name of Local Health District***) being the duly appointed delegate of the Director-General of the Department of Health in accordance with section 21 of the Health Administration Act 1982 and subject to this authority:

Do hereby approve the attached formulary pursuant to the provisions of section 17A (1b) of the Poisons and Therapeutics Goods Act 1966, I authorise (***insert name of Nurse Practitioner***) while employed by the (***insert name of Facility/LHD***) as a Nurse Practitioner to possess, use, supply or prescribe poisons and restricted substances and drugs of addiction within the attached formulary for the purposes of the practice of their profession as Nurse Practitioner.

Dated this \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ day of \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 20

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (signature)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (name)